The FDA has granted granted 510(k) clearance for Belkin Vision's Eagle device designed to perform selective laser trabeculoplasty (SLT). The Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser is the first and only contactless laser for glaucoma, providing an automated and noninvasive solution, according to the manufacturer.

The Eagle laser offers several advantages over traditional treatment options, a company news release states. One key advantage is there is no need for the use of a gonioscopy lens; the laser energy is delivered in a noncontact procedure directly through the limbus to the trabecular meshwork. The device also automatically defines the target location and then applies the laser treatment sequence with its eye tracker compensating for any eye movement. Belkin said Eagle direct SLT (DSLT) is a streamlined, user-friendly technology that can expand access to early laser therapy by enabling more eye care professionals to perform the procedure.

"We believe that this FDA clearance will have a positive impact on the lives of those affected by glaucoma, offering novel treatment methods and renewed hope for the future," Belkin Vision CEO, Daria Lemann-Blumenthal stated in a news release.